Filtered By:
Condition: Thrombosis
Therapy: Thrombolytic Therapy

This page shows you your search results in order of relevance. This is page number 5.

Order by Relevance | Date

Total 1360 results found since Jan 2013.

The iScore Predicts Clinical Response to Tissue Plasminogen Activator in Korean Stroke Patients
Background: Despite substantial differences in clinical features between Asian and Western stroke patients, there are no published prognostic tools validated in an Asiatic population for thrombolytic therapy. We assessed the ability of the iScore to predict the clinical response after intravenous thrombolysis with tissue plasminogen activator (tPA) in a Korean stroke population.Methods: We applied the iScore to eligible participants in the nationwide multicenter stroke registry in Korea. Main outcome measures were poor functional outcome defined as having a modified Rankin Scale score 3-6 and death at 3 months. Symptomati...
Source: Journal of Stroke and Cerebrovascular Diseases - June 24, 2013 Category: Neurology Authors: Tai Hwan Park, Sang-Soon Park, Youngchai Ko, Soo Joo Lee, Kyung Bok Lee, Jun Lee, Kyusik Kang, Jong-Moo Park, Jay Chol Choi, Dong-Eog Kim, Yong-Jin Cho, Keun-Sik Hong, Joon-Tae Kim, Dae-Hyun Kim, Jae-Kwan Cha, Moon-Ku Han, Ji Sung Lee, Juneyoung Lee, Kyun Tags: Original Articles Source Type: research

Serum Albumin Is Associated with Cerebral Hemorrhage in Post-Intravenous Thrombolytic Therapy for Acute Stroke : A Retrospective Chart Review (P4.222)
CONCLUSION: Albumin may provide additional protection against hemorrhagic conversion after IV thrombolytic use in acute ischemic stroke. Study Supported by: noneDisclosure: Dr. Kamal has nothing to disclose. Dr. Li has nothing to disclose. Dr. Smith has nothing to disclose. Dr. Mustafa has nothing to disclose. Dr. Sawyer has nothing to disclose. Dr. Ching has nothing to disclose. Dr. Mehta has received personal compensation for activities with Biogen Idec, and Teva Neuroscience as a speaker, and with the Gerson Lehrman Group as a consultant.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Kamal, H., Li, P., Smith, K., Mustafa, G., Sawyer, R., Ching, M., Mehta, B. Tags: Cerebrovascular Disease and Interventional Neurology: Acute Stroke Thrombolysis Source Type: research

Strategic Planning to Reduce the Burden of Stroke Among Veterans: Using Simulation Modeling to Inform Decision Making Clinical Sciences
Conclusions— Prevention strategies tend to have larger population impacts, though interventions targeting specific high-risk groups tend to be more efficient in terms of number-needed-to-treat per QALY gained.
Source: Stroke - June 23, 2014 Category: Neurology Authors: Lich, K. H., Tian, Y., Beadles, C. A., Williams, L. S., Bravata, D. M., Cheng, E. M., Bosworth, H. B., Homer, J. B., Matchar, D. B. Tags: Health policy and outcome research Clinical Sciences Source Type: research

Transcranial Laser Therapy in Acute Stroke Treatment: Results of Neurothera Effectiveness and Safety Trial 3, a Phase III Clinical End Point Device Trial Major Clinical Trial
Conclusions— Once the results of the interim futility analysis became available, all study support was immediately withdrawn by the capital firms behind PhotoThera, and the company was dissolved. Proper termination of the trial was difficult but was finally achieved through special efforts by former employees of PhotoThera, the CRO Parexel and members of the steering and the safety committees. We conclude that transcranial laser therapy does not have a measurable neuroprotective effect in patients with acute ischemic stroke when applied within 24 hours after stroke onset. Clinical Trial Registration— URL: http...
Source: Stroke - October 27, 2014 Category: Neurology Authors: Hacke, W., Schellinger, P. D., Albers, G. W., Bornstein, N. M., Dahlof, B. L., Fulton, R., Kasner, S. E., Shuaib, A., Richieri, S. P., Dilly, S. G., Zivin, J., Lees, K. R., for the NEST 3 Committees and Investigators, Broderick, Ivanova, Johnston, Norrvin Tags: Acute Cerebral Infarction Major Clinical Trial Source Type: research

Burden of stroke in Italy: An economic model highlights savings arising from reduced disability following thrombolysis
ConclusionOur study reveals that performing thrombolytic therapy in eligible patients improves economic outcomes compared with patients receiving standard care. This model is useful for decision makers, both within and outside of the Italian national context, as a tool to assess the cost‐effectiveness of thrombolysis in both short‐ and long‐term period.
Source: International Journal of Stroke - April 8, 2015 Category: Neurology Authors: M. Chiumente, M. M. Gianino, D. Minniti, T. J. Mattei, B. Spass, K. M. Kamal, D. E. Zimmerman, A. Muca, E. Luda Tags: Research Source Type: research

Impact of Prehospital Intervention on Delay Time to Thrombolytic Therapy in a Stroke Center with a Systemized Stroke Code Program
The use of emergency medical services (EMS) and notification to hospitals by paramedics for patients with suspected stroke are crucial determinants in reducing delay time to acute stroke treatment. The aim of this study is to investigate whether EMS use and prehospital notification (PN) can shorten the time to thrombolytic therapy in a stroke center with a systemized stroke code program.
Source: Journal of Stroke and Cerebrovascular Diseases - April 6, 2016 Category: Neurology Authors: Dae-Hyun Kim, Hyun-Wook Nah, Hyun-Seok Park, Jae-Hyung Choi, Myong-Jin Kang, Jae-Taeck Huh, Jae-Kwan Cha Source Type: research

Thrombolytic therapy in ischemic stroke patients with pre-stroke depression in the telestroke vs non-telestroke
This study aims to examine clinical risk factors associated with inclusion or exclusion for rtPA in acute ischemic stroke populations with pre-stroke depression in the telestroke versus a non-telestroke setting.
Source: Journal of Stroke and Cerebrovascular Diseases - August 15, 2020 Category: Neurology Authors: Robyn Moraney, Nicolas Poupore, Rachel Shugart, Mandy Tate, Ashley Snell, Katherine Brown, Thomas I. Nathaniel Source Type: research

Decompressive Hemicraniectomy for Malignant Hemispheric Stroke in the Elderly: Comparison of Outcomes between Individuals 61-70 and >70 Years of Age
Conclusions: We suggest that the efficacy of DHC in malignant hemispheric stroke patients between 61 and 70 years of age be further investigated in future randomized trials. By contrast, it appears unlikely that patients>70 years of age would benefit from DHC.
Source: Journal of Stroke and Cerebrovascular Diseases - March 13, 2013 Category: Neurology Authors: Joji Inamasu, Takafumi Kaito, Takeya Watabe, Tsukasa Ganaha, Yasuhiro Yamada, Teppei Tanaka, Shuei Imizu, Takuro Hayashi, Motoharu Hayakawa, Yoko Kato, Yuichi Hirose Tags: Original Articles Source Type: research

Prehospital factors determining regional variation in thrombolytic therapy in acute ischemic stroke
ConclusionsThese results suggest that the larger proportion of patients arriving within 4·5 h in the centralized model might be related to a lower threshold to use emergency services to transport stroke patients and partly to preferential referral of thrombolysis candidates.
Source: International Journal of Stroke - December 23, 2013 Category: Neurology Authors: Maarten M. H. Lahr, Patrick C. A. J. Vroomen, Gert‐Jan Luijckx, Durk‐Jouke Zee, Ronald Vos, Erik Buskens Tags: Research Source Type: research

Combination Treatment With N-Acetyl-Seryl-Aspartyl-Lysyl-Proline and Tissue Plasminogen Activator Provides Potent Neuroprotection in Rats After Stroke Basic Sciences
Conclusions— Our data indicate that AcSDKP passes the blood–brain barrier, and that treatment of acute stroke with AcSDKP either alone at 1 hour or in combination with tPA at 4 hours of the onset of stroke is effective to reduce ischemic cell damage in a rat model of embolic stroke. Inactivation of TGF-β and NF-B signaling by AcSDKP in the neurovascular unit may underlie the neuroprotective effect of AcSDKP.
Source: Stroke - March 24, 2014 Category: Neurology Authors: Zhang, L., Chopp, M., Teng, H., Ding, G., Jiang, Q., Yang, X. P., Rhaleb, N. E., Zhang, Z. G. Tags: Acute Cerebral Infarction Basic Sciences Source Type: research

Thrombolytic therapy for stroke in patients with preexisting cognitive impairment
Conclusions: Ischemic stroke patients with PSCI should receive rtPA if they are eligible. This conclusion cannot be extended to severe cognitive impairment or severe strokes. Classification of evidence: This study provides Class IV evidence that in patients with PSCI presenting with acute ischemic stroke, IV rtPA improves outcomes.
Source: Neurology - June 9, 2014 Category: Neurology Authors: Murao, K., Leys, D., Jacquin, A., Kitazono, T., Bordet, R., Bejot, Y., Kimura, K., Godefroy, O., Wakisaka, Y., Moulin, S., Ago, T., Sibon, I., Bombois, S., Mas, J.-L., Henon, H., Pasquier, F., Giroud, M., Cordonnier, C., Okada, Y., On behalf of the OPHELI Tags: All Cerebrovascular disease/Stroke, All Cognitive Disorders/Dementia, MCI (mild cognitive impairment), Infarction ARTICLE Source Type: research

Multicenter clinical experience in over 125 patients with the Penumbra Separator 3D for mechanical thrombectomy in acute ischemic stroke
Conclusions The results suggest that the Separator 3D enables safe and effective revascularization of occluded large arteries in acute stroke intervention, leading to a high rate of functional independence at 90 days.
Source: Journal of NeuroInterventional Surgery - December 13, 2015 Category: Neurosurgery Authors: Behme, D., Kowoll, A., Mpotsaris, A., Hader, C., Hechelhammer, L., Weber, J., Weber, W. Tags: Ischemic stroke Source Type: research

90 Day Outcome after Reperfusion Therapy of Stroke Patients with Baseline Disability: Unique Observations from Patients Treated on the Mobile Stroke Unit (P6.052)
Conclusion: In comparison to previously published data our analysis shows unfavorable outcome in the majority of patients with baseline disability who received thrombolytic therapy. The small sample size is a limitation to this analysis, and further studies are needed to assess if this subpopulation should be included in clinical trials assessing new therapies or modalities to deliver them.Disclosure: Dr. almaghrabi has nothing to disclose. Dr. Sarraj has nothing to disclose. Dr. Bowry has nothing to disclose. Dr. Parker has nothing to disclose. Dr. Yamal has nothing to disclose. Dr. Grotta has received personal compensati...
Source: Neurology - April 3, 2016 Category: Neurology Authors: Almaghrabi, T., Sarraj, A., Bowry, R., Parker, S., Yamal, J.-M., Grotta, J. Tags: Prehospital Stroke Care and Uses of NIHSS Source Type: research

Utility of items of baseline NIH stroke scale as predictors of functional outcomes 3 months after mild ischemic stroke
We examined the utility of individual NIH Stroke Scale (NIHSS) score items or clusters of items as predictors of f unctional outcomes 3 months after mild stroke.
Source: Journal of Stroke and Cerebrovascular Diseases - March 18, 2017 Category: Neurology Authors: Jay Chol Choi, Jun Lee, Jae-Kwan Cha, Joon-Tae Kim, Hee-Joon Bae Source Type: research